Medica mente 1, 2015 1, 2015 Medica mente

. ,
1. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop Dj., Horwitz E. Minimal criteria for defining multipotent
, . mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4): 3157.
1012 - 2. Eaves C.J. Hematopoietic stem cells: concepts, definitions, and the new reality. Blood. 2015 Apr 23; 125(17): 260513.
[4]. - G-- 3. Mndez-Ferrer S., Scadden D.T., Snchez-Aguilera A. Bone marrow stem cells: current and emerging concepts. Ann N Y Acad Sci. 2015 Jan; 1335: 3244.
- . , 4. Roselli E.A., Lazzati S., Iseppon F., Manganini M., Marcato L., Gariboldi M.B., Maggi F., Grati F.R., Simoni G. Fetal mesenchymal stromal cells from cryopre-
served human chorionic villi: cytogenetic and molecular analysis of genome stability in long-term cultures. Cytotherapy. 2013 Nov; 15(11): 134051.
in vitro , - G- -
5. Sabapathy V., Sundaram B., Mankuzhy P., Kumar S. Human Whartons Jelly Mesenchymal Stem Cells plasticity augments scar-free skin wound healing with
. . - hair growth. PLoS One. 2014 Apr 15; 9(4): e93726.
FISH 6. Guidelines for the Clinical Translation of Stem Cells, International Society forStem Cell Research. 2008: 119.
, (fluorescent in situ hybridization) - 7. Mayshar Y., Ben-David U., Lavon N., Biancotti J.C., Yakir B., Clark A.T., Plath K., Lowry W.E., Benvenisty N. Identification and classification of chromosomal
aberrations in human induced pluripotent stem cells. Cell Stem Cell. 2010; 7: 52131.
. - .
8. Amps K., Andrews P.W., Anyfantis G., Armstrong L., Avery S., Baharvand H., Baker J., Baker D., Munoz M.B., Beil S. et al. Screening ethnically diverse human embryonic
, - stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011; 29:113244.
, , 9. Wang Y., Zhang Z., Chi Y., Zhang Q., Xu F. et al. Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malig-
, , nant transformation. Cell Death Dis. 2013 Dec 5; 4: e950.
. - , . 10. Kim J.A., Im K.O., Park S.N., Kwon J.S. et al. Cytogenetic heterogeneity and their serial dynamic changes during acquisition of cytogenetic aberrations in cul-
tured mesenchymal stem cells. Mutat Res. 2015 Jul; 777: 608.
, -
, , . ,
array-
, - CGH .
, , , J.-A. Kim .
. 7

( )
FISH , -
7
(Guidelines for the Clinical Translation of Stem Cells), ( FISH).
- ,
.. , ...; .. , ...; .. , ..
(the International Society for Stem Cell Research). 7, -
- ,
. .. ,
, , 7 [10]. -
- , FISH- -
[6]. -
.
. -
.
. - : -
- . ,
- ? J.-A. Kim ., ,
G-, G-- , ,
. , - (46,XY,der(7)dup(7)(q32q36)t(7;?)(q36;?)[1]/46,XY[14]) .
, .
. ,
, 7
: , , , -
, (46,XY,der(7)dup(7)(q32q36)t(7;?)(q36;?) [20]) - ,
1, 12, 17 20, - 16- [10].
. , , ,
, N. Benvenisty . - 4 14
, [2, 5, 4]. -
104 , 66 14 19, - (NBS)
38 - - , NBS1 5 6 NBS1 657
, 18 - [4]. , - del 5 657661 del . NBS1
. ~20% , , , - 90% ,
~9% [7]. - - [1, 2, 4]. -
P.W. Andrews . - - [1, 2, 4]. NBS 23--
34% 129 [8]. , . 10 - , - : O, , ,
, - 200 - 1981 . , , -
, 20 54%. , C. Weemaes [7]. : ,
Y. Wang . 9 , , , - .
3 30 : . CD3+, CD19+,
, 7 1 [4]. : , , - CD4+, CD4+/CD8+, IgA, IgG,
(CNV) , - , . IgG2. -
10 . - - - [5, NBS 50 , -
- . 6]. , 1000 [7, 8].
, 8 1998 . NBS1 [4]. ,
, 20 : , -
[9]. , . , - , . -
12 13
Medica mente 1, 2015 1, 2015 Medica mente

1. 46, (20) .
. . Hb . / / . . . (. 1)
, 17 -
(109/) (1012/) (/) (109/) (%) (%) (%) (%) (%) (%)
: . .
6 .. 12,4 4,88 164 455 48 1 47 13 20 19
.
13 .. 8,7 3,66 126 571 64 1 63 5 24 7
4 3,7 4,56 155 397 42 1 68 17 24 13 - -
6 3,17 4,62 125 310 40 3 61 9 35,6 14,8 .. . -

(. 1). --
, , , ,
, , , ( : 2,81,21.0; 2,01,21,0 = 5,76 3).
, . - ,
NBS -
1 . ,
- -
-
. , .
..., ..
( ). -
, -
. 3 - -
(1- , 2 - . 657del5 NDS1.
) 29 . 1. -
II - (. 2),
, . 30 3 10,5 , 89,5 .
- - -
0,7 , - -
(). 32 , - 2,53 .
, 6
( ). 2, - , . - . - : - 2. - .
40 . - (), -
, 8/9 . , . - , () , -
2225 , 45 , - () : - ( - .
28,5 , 32 . 1 , - ), , -
, ( ). - -
, , , , .
. - (. 1). : . , -
- (0,4 ). - ,
- . - - ,
, . (1766 ). CD3+, CD19+, CD4+, CD4+/CD8+, -
. : IgA, IgG (. 2). . -
1 2- -
- -
2. () ()
/
. (, , , ), NBS
. 95% IgG 0,4 / 2- . -
IgA 50,3 / 14-108 , 1 34 . - -
IgG 535 / 500-1200 , -
IgM 91 / 43-239 , .
. ( )
(1 )
1. The International Nijmegen Breakage Syndrome Study Group: Nijmegen breakage syndrome. Arch Dis Child. 2000; 82: 4006.
% 109 / % 109/ 2. Kondratenko I., Paschenko O., Plyakov A., Bologov A. Nijmegen breakage syndrome. Adv Exp Med Biol. 2007; 601: 617.
1 CD3 40 0,65 65 (5070) 4,4 (2,35,9) 3. Seemanova E., Passarge E., Beneskova D. et al. Familial microcephaly with normal intelligence, immunodeficiency, and risk for lymphoreticular malignancies:
a new autosomal recessive disorder. Am J Med Genet. 1985; 20: 63948.
2 CD4+CD3 26 0,42 - 3,2 (1,55,0) 4. MIM 602667, OMIM 251260
3 CD8+CD3 10 0,16 - 1,0 (0,61,5) 5. .., .., .. : , .
4 CD4/CD8 2,6 - 2,9 (1,87) - . 2005; 1/2(23): 10511.
6. Wegner R., Metzger M., Hanefeld F. A new chromosomal instability disorder confirmed by complementation studies. Clin Genet. 1988; 33: 2032.
5 CD3+HLA-DR+ 4 0,06 - 0,1 (0,10,3) - 7. Matsuura S., Weemaes C., Smeets D. et al. Genetic mapping using microcell-mediated chromosome transfer suggests a locus for Nijmegen breakage syn-
6 CD19 11 0,18 28 (1936) 1,7 (1,22,8) drome at chromosome 8q21-24. Am J Hum Genet. 1997; 60: 148794.
8. Seidemann K., Henze G., Beck J. et al. Non-Hodgkin lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from
7 CD16+56+CD3- 43 0,70 6 (311) 0,4 (0,30,9) NK the BFM trials. Ann Oncol. 2000; 11 (Suppl. 1): 1415.

14 15
Medica mente 1, 2015 1, 2015 Medica mente

1. 46, (20) .
. . Hb . / / . . . (. 1)
, 17 -
(109/) (1012/) (/) (109/) (%) (%) (%) (%) (%) (%)
: . .
6 .. 12,4 4,88 164 455 48 1 47 13 20 19
.
13 .. 8,7 3,66 126 571 64 1 63 5 24 7
4 3,7 4,56 155 397 42 1 68 17 24 13 - -
6 3,17 4,62 125 310 40 3 61 9 35,6 14,8 .. . -

(. 1). --
, , , ,
, , , ( : 2,81,21.0; 2,01,21,0 = 5,76 3).
, . - ,
NBS -
1 . ,
- -
-
. , .
..., ..
( ). -
, -
. 3 - -
(1- , 2 - . 657del5 NDS1.
) 29 . 1. -
II - (. 2),
, . 30 3 10,5 , 89,5 .
- - -
0,7 , - -
(). 32 , - 2,53 .
, 6
( ). 2, - , . - . - : - 2. - .
40 . - (), -
, 8/9 . , . - , () , -
2225 , 45 , - () : - ( - .
28,5 , 32 . 1 , - ), , -
, ( ). - -
, , , , .
. - (. 1). : . , -
- (0,4 ). - ,
- . - - ,
, . (1766 ). CD3+, CD19+, CD4+, CD4+/CD8+, -
. : IgA, IgG (. 2). . -
1 2- -
- -
2. () ()
/
. (, , , ), NBS
. 95% IgG 0,4 / 2- . -
IgA 50,3 / 14-108 , 1 34 . - -
IgG 535 / 500-1200 , -
IgM 91 / 43-239 , .
. ( )
(1 )
1. The International Nijmegen Breakage Syndrome Study Group: Nijmegen breakage syndrome. Arch Dis Child. 2000; 82: 4006.
% 109 / % 109/ 2. Kondratenko I., Paschenko O., Plyakov A., Bologov A. Nijmegen breakage syndrome. Adv Exp Med Biol. 2007; 601: 617.
1 CD3 40 0,65 65 (5070) 4,4 (2,35,9) 3. Seemanova E., Passarge E., Beneskova D. et al. Familial microcephaly with normal intelligence, immunodeficiency, and risk for lymphoreticular malignancies:
a new autosomal recessive disorder. Am J Med Genet. 1985; 20: 63948.
2 CD4+CD3 26 0,42 - 3,2 (1,55,0) 4. MIM 602667, OMIM 251260
3 CD8+CD3 10 0,16 - 1,0 (0,61,5) 5. .., .., .. : , .
4 CD4/CD8 2,6 - 2,9 (1,87) - . 2005; 1/2(23): 10511.
6. Wegner R., Metzger M., Hanefeld F. A new chromosomal instability disorder confirmed by complementation studies. Clin Genet. 1988; 33: 2032.
5 CD3+HLA-DR+ 4 0,06 - 0,1 (0,10,3) - 7. Matsuura S., Weemaes C., Smeets D. et al. Genetic mapping using microcell-mediated chromosome transfer suggests a locus for Nijmegen breakage syn-
6 CD19 11 0,18 28 (1936) 1,7 (1,22,8) drome at chromosome 8q21-24. Am J Hum Genet. 1997; 60: 148794.
8. Seidemann K., Henze G., Beck J. et al. Non-Hodgkin lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from
7 CD16+56+CD3- 43 0,70 6 (311) 0,4 (0,30,9) NK the BFM trials. Ann Oncol. 2000; 11 (Suppl. 1): 1415.

14 15